ISSN:
1432-0533
Keywords:
Key words: Ki-67 – Cell kinetics – Nervous system tumors – Monoclonal antibody – Prognosis
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract. Paraffin-embedded surgical specimens from 136 primary human central nervous system (CNS) tumors, including 50 meningiomas, 24 astrocytomas, 26 anaplastic astrocytomas, 9 glioblastomas, 8 oligodendrogliomas, 4 ependymomas, 1 anaplastic ependymoma, 2 subependymomas, 9 medulloblastomas, and 3 paragangliomas, were immunostained, following microwave processing, using a streptavidin/peroxidase method and the MIB 1 monoclonal antibody (mAb) against the Ki-67 antigen. The following mean Ki-67 labeling index (LI) values±SD were found: meningiomas, 2.47±1.83; astrocytomas, 2.03±2.03; anaplastic astrocytomas, 12.80±6.29; glioblastomas, 14.57±6.77; oligodendrogliomas, 5.06±4.78; ependymomas, 2.63±2.58; anaplastic ependymoma, 6.89; subependymomas, 1.79±1.54; medulloblastomas, 18.77±9.65; and paragangliomas, 2.19±2.51. Our findings indicate that while malignant CNS tumors always exhibited high Ki-67 LI values, and benign CNS tumors generally displayed lower values, increased immunoreactivity for Ki-67 epitopes (Ki-67 LI higher than 4) was noted in a number of meningiomas, astrocytomas, ependymomas, oligodendrogliomas and paragangliomas, contrasting with their benign histological features. Further investigations of the Ki-67 immunoreactivity in CNS tumors and systematic correlation with the postoperative follow-up of patients are necessary to determine the value of Ki-67 LI in predicting the biological behavior of CNS neoplasms.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00386253
Permalink